Updates
What's New in AusDI – May 2025
Browse the latest AusDI drug updates and medicines information – created and curated by trusted Australian editorial pharmacists, monthly.
Drug Monographs
Content Updates to Monographs
As part of our rigorous editorial updating process, the AusDI editorial team monitors safety information issued by the Australian Therapeutic Goods Administration (TGA), the U.S. Food & Drug Administration (FDA), the European Medicines Agency (EMA), the New Zealand Medicines and Medical Devices Safety Authority (Medsafe), and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). FDA-approved indications and dosing information in adults and children are also reviewed by our editorial team and included in selected monographs.
The Acetazolamide (Systemic) monograph has been updated with information on non-cardiogenic pulmonary oedema based on changes to product information. Cases of non-cardiogenic pulmonary oedema have been reported with acetazolamide (including severe cases occurring after a single dose) and have typically occurred within minutes to hours after administration of acetazolamide. If non-cardiogenic pulmonary oedema is suspected, it is recommended that acetazolamide be withdrawn and supportive treatment given. It is recommended that acetazolamide not be administered to patients who have previously experienced non-cardiogenic pulmonary oedema with acetazolamide.
Past Content Updates
April 2025
The Isotretinoin (Systemic) monograph has been updated with information on sexual disorders based on changes to product information. Anhedonia, decreased libido, erectile dysfunction, gynaecomastia, and vulvovaginal dryness have been reported with isotretinoin. It is recommended that patients be asked about signs or symptoms of sexual dysfunction before starting isotretinoin treatment, and monitored during treatment for the development of new sexual disorders. Discontinuation of isotretinoin treatment may not alleviate symptoms and further specialist evaluation may be required.
March 2025
The Influenza Virus Vaccine (Systemic) monograph has been updated with information for the Australian 2025 influenza season. The composition of the 2025 vaccine differs from the 2024 southern hemisphere and 2024/2025 northern hemisphere recommendations with the inclusion of one new strain for the influenza A(H3N2) subtype virus component.
February 2025
The Bupropion (Systemic) monograph has been updated with information on Brugada syndrome based on changes to product information. The use of bupropion may unmask Brugada syndrome, a rare genetic disease of the cardiac sodium channel characterised by electrocardiogram (ECG) changes, which may result in cardiac arrest and/or sudden death. Caution is recommended in patients with Brugada syndrome or risk factors such as a family history of cardiac arrest or sudden death.
New Product Summary
Apohealth Allergy and Hayfever Relief
Chemists' Own Favic for Cold Sores
Chemists' Own Melatonin Sleep Aid
Medsurge Magnesium Sulfate Heptahydrate
Prazosin Hydrochloride USP [Novitium Pharma]
New Product Information
Apohealth Allergy And Hayfever Relief Nasal Spray
Product information with an update to safety includes Abrysvo, Ajovy, Aldurazyme, Allosig, Apo-Allopurinol, Apo-Azathioprine, Apo-Esomeprazole, Apo-Ezetimibe/Simvastatin, Apo-Isotretinoin, Apo-Rabeprazole, Apretude, Austrapen, Avonex, Azathioprine Sandoz, Bavencio, Brufen Plus, Brufen Tablets, Budenofalk Foam, Caldolor, Caprelsa, Ceftriaxone Viatris, Celebrex, Clarithro, Clopixol, Clozaril, Cosentyx, Cozaar, Darzalex, DBL Dexamethasone Sodium Phosphate, Depo-Medrol, Depo-Nisolone, Diprivan, Emgality, Entrip, Epkinly, Esomeprazole Viatris, Ezetrol, Fluconazole Sandoz Capsules, Fluorescite, Fonat, Gilenya, Halaven, Hemlibra, Humira, Inflectra, Kimmtrak, Leflunomide Sandoz, Lenvima, Levoxine, Lynparza Tablets, Menveo, Mersynofen, Nplate, Ocrevus, Olumiant, Oratane, Ovestin Tablets, Ozempic, Ozole, Paxlovid, Plegridy, Precedex, Precedex Ready to Use, Primoteston Depot, Primovist, Provive, Relfydess, Solu-Cortef, Solu-Medrol, Sunitinib Sandoz, Sunlenca, Tecentriq, Tecentriq SC, Tecvayli, Telfast Decongestant, Thioprine, Tolak 4% Once Daily, Tramadol Sandoz Injection, Tramadol Sandoz SR, Trikafta, Trileptal, Trodelvy, Twinrix Preservative Free, Zabep, Zeposia, and Zyloprim.
Product information with an update to indications includes Boostrix-IPV, Cresemba, Enhertu, Fasenra, Kisqali, Sandoz Lamotrigine, and Venclexta.
Try AusDI for FREE
To try one of Australia’s most efficient and comprehensive drug information databases, register for a 14-day FREE trial by filling in the form below.
We’ll be in touch with more information to help you get started soon.